

| Leadership | | Aganda |
|--|------------------|--|
| Chair: Lajos Pusztai, MD, PhD | | Agenda |
| Vice-Chair:Priyanka Sharma, MD | 4:15 - 4:20 pm | Welcome and Introductions - Lajos Pusztai, MD, DPhil |
| Executive Officer: Anne Chiang, MD, PhD | | (Chair) and Priyanka Sharma, MD (Vice-chair) |
| Statisticians: | | Educational Session |
| Danika Lew, MA | De-Novo Stage I\ | / Breast Cancer: Time to Reconsider Treatment Paradigms? |
| | _ | |
| Scientific Leadership | 4:20 - 4:35 pm | Update on staging and evolving clinical presentation - |
| Translational Medicine: Alastair M. Thompson, MD | | Jennifer Plichta, MD, MS, Duke Cancer Institute |
| Andrew K. Godwin, PhD | 4:35 - 4:50 pm | Optimization of systemic and local therapy for De- |
| Radiation Oncology: Reshma Jagsi, MD | • | novo stage IV breast cancer - |
| Surgery: Joshua M.V. Mammen, MD, PhD | | Mariya Rozenblit, MD, Yale School of Medicine |
| Imaging:TBD | | • |
| Pathology:David L. Rimm, MD, PhD | 4:50 - 5:05 pm | Q&A |
| Early Therapeutics:Stephanie L. Graff, MD | 1 | Committee Business and Updates |
| Designates | F.OF F.1F 12 12 | Dublication wadata Allican Maisney DhD |
| Adolescent & Young Adults: Erin Elizabeth Roesch, MD | 5:05 - 5:15 pm | Publication update – Allison Meisner, PhD |
| Cancer Control Liaisons: Mariya Rozenblit, MD (Survivorship) | 5:15 - 5:25 pm | Patient Advocate update – |
| Dawn L. Hershman, MD (Cancer Care Delivery) | | Ginny Mason and Roberta Albany |
| Banu Arun, MD (Prevention) | 5:25 - 5:35 pm | Translational Medicine Sub-Committee update - |
| Helen K. Chew, MD (Symptom Management) | 3.23 - 3.33 pm | Alastair Thompson, MD and Andrew K. Godwin, PhD |
| NCORP Representative: | | Alastali Thompson, MD and Andrew N. Godwin, Fib |
| Veterans Affairs:Sarah V. Colonna, MD | 5:35 - 6:05 pm | Review of open CTSU trials |
| Data Coordinators:Aubrey Gilmore, BA | 6:05 - 6:15 pm | Reports from Committee Liaisons |
| Gabi Herbert, MS, BS | 0.05 0.15 pm | reports from committee Europis |
| Larry G. Kaye | | NCORP: Philip Lammers, MD |
| Kevin Moralda, BS | | Symptom Management: Lynn Henry, MD, PhD |
| Oncology Research Professionals: | | Radiotherapy: Reshma Jagsi, MD, PhD |
| CRAs: Karyn N. Hart, CCRP | | Surgery: Joshua Mammen, MD |
| Nurse: Cameo Windham, BSN, RN | | Cancer Care Delivery: Dawn Hershman, MD |
| Patient Advocates: Roberta A. Albany | | Prevention: Banu Arun, MD |
| Ginny Mason, RN, BSN | | Theranostics Subcommittee: Shane Stecklein, MD, PhD |
| Pharmaceutical Science: Jorge G. Avila, PharmD | | & Joanne Mortimer, MD |
| Dawud Nael Dawud Ellayan, Pharm D | | Early Therapeutics: Stephanie Graff, MD |
| Protocol Project Manager: | 6:15 pm | Closing Comments and Adjourn |
| | | |

Time/Location

Friday, September 19, 2025 4:15 p.m. - 6:15 p.m. Room: Regency A (Ballroom Level, West Tower)

Concepts in Development

S2511, "Randomized Phase III trial of multimodality therapy versus standard of care systemic therapy in HER2 positive (HER2+) de novo (AJCC stage IV) oligometastatic breast cancer with response to initial chemotherapy." Submitted: 5/16/25



- **52512**, "ARIA: A Randomized Phase III Trial of Two vs. Three Years of Adjuvant Ribociclib In the Treatment of High-Risk, Hormone Receptor-Positive EArly-Stage Breast Cancer" Submitted: 6/13/25
- **S2602**, "A Phase II Trial Treating Molecular Relapse in Early Stage Triple Negative Breast Cancer (DETECT-Pilot)" Submitted: TBD

Active Studies

- <u>\$2206</u>, "Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer." Drs. Cobain and Pusztai. Activated: 10/30/23.
- **S2212**, "Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study." Drs. Sharma and Mitri. Activated: 7/21/23.
- CTSU/A011801, "The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib." Dr. O'Sullivan. SWOG Champion: Dr. Murthy. Activated: 1/6/21.
- CTSU/CCTG MA.39, "Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer." Dr. Whelan. SWOG Champion: Dr. Jagsi. Activated: 5/30/18.
- CTSU/NRG-BR007, "A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)." Dr. White. SWOG Champion: Dr. Shumway. Activated: 6/7/21.

Closed Studies

- **51418**, "A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with ≥1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) after Neoadjuvant Chemotherapy." Drs. Pusztai and Mammen. Activated: 11/15/16; Permanently closed: 6/30/21.
- **<u>\$1207</u>**, "Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e^3 Breast Cancer Study-Evaluating Everolimus with Endocrine Therapy." Drs. Chavez-MacGregor and Pusztai. Activated: 9/4/13; Permanently closed: 5/1/19.

- **S1706**, "A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer." Drs. Jagsi and Chalasani. Activated: 9/12/18. Permanently closed: 7/1/24.
- **S2007**, "A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases." Drs. Brenner and Kaklamani. Activated: 12/15/20. Permanently closed: 4/7/25.
- CTSU/A011202, "A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy." Dr. Boughey. SWOG Champion: Dr. Mammen. Activated: 2/7/14; Permanently closed: 7/1/22.
- CTSU/EA1181, "(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer)" Dr. Tung. SWOG Champions: Breast Committee: Dr. Tang, Imaging Committee: Dr. Lu. Activated: 2/11/20; Permanently closed: 10/19/23.
- CTSU/EA1183, "FDG PET to Assess Therapeutic Response in Patients with Bone-Dominant Metastatic Breast Cancer, FEATURE." Dr. Specht. SWOG Champions: Breast Committee: Dr. Linden, Imaging Committee: Dr. Wright. Activated: 4/2/20; Permanently closed: 12/22/23.
- CTSU/NRG-BR002, "A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer." Drs. Chmura and White. SWOG Champion: Dr. Jagsi. Activated: 12/24/14; Permanently closed: 5/27/22.
- CTSU/NRG-BR003, "A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer." Dr. Valero. SWOG Champion: Dr. Makhoul. Activated: 6/26/15; Permanently closed: 4/22/22.
- CTSU/NRG-BR004, "A Randomized, Double-Blind, Phase III Trial of Taxane/ Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer." Dr. Geyer. SWOG Champion: Dr. Cobain. Activated: 3/12/19; Permanently closed: 7/1/22.



CTSU/NRG-BR005, "A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment without Surgery." Dr. Basik. SWOG Champion: Dr. Thompson. Activated: 4/13/17; Permanently closed: 12/2/22.

Active Cancer Survivorship Study

S1501, "Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III." Drs. Floyd and Leja. Activated: 9/15/17. Arms 1 and 2 permanently closed to accrual: 11/1/24.

Closed Symptom Control and Quality of Life Studies

S1614, "A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors." Drs. Hwang and Lok. Activated: 2/21/19; Permanently closed: 11/15/22.

S1714, "A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients." Drs. Trivedi and Hershman. Activated 3/1/19; Permanently closed: 11/15/21.

Active Cancer Care Delivery Studies

51703, "Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer." Drs. Accordino and Hershman. Activated: 7/16/18.

Closed Cancer Prevention Study

<u>S1904</u>, "Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice among Women with Atypical Hyperplasia or Lobular Carcinoma In Situ – Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE)." Drs. Crew, and Kukafka. Activated: 9/1/20. Permanently closed: 6/14/24. CTSU/EA1151, "Tomosynthesis Mammographic Imaging Screening Trial (TMIST)." Dr. Pisano. SWOG Champion: Dr. Arun. Activated: 7/6/17. Closed to accrual: 12/20/24.

Closed Early Therapeutics and Rare Cancers Studies

S1609, "DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors." Drs. Patel and Chae. Activated 1/13/17; Permanently closed: 3/15/23.

CTSU/EAY131, "Molecular Analysis for Therapy Choice (MATCH)". Dr. Flaherty. Activated 8/12/15; Permanently closed: 12/30/22.

Publications

The publications listed below were received by the Group Chair's Office as published (including online), accepted, or submitted since the SWOG Spring 2025 Group Meeting. Conference abstracts are not included.

Because of journal embargo policies, journal names are omitted for submitted or accepted manuscripts.

Published/Accepted Manuscripts

S1007 Race and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Positive BC in the Phase III RxPONDER Trial (SWOG S1007). Abdou Y, Barlow W, Gralow J, Meric-Bernstam F, Albain K, Hayes D, Lin N, Perez E, Goldstein L, Chia S, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Schott A, Shak S, Sharma P, Lew D, Miao J, Unger J, Tripathy D, Pusztai L, Hortobagyi G, Kalinsky K. Journal of the National Cancer Institute May 1;117(5):889-897, 2025.

https://pubmed.ncbi.nlm.nih.gov/39656951/

Submitted Manuscripts

S1007 Ovarian Reserve as a Measure of Adjuvant Chemotherapy Benefit in Women with Hormone Receptor Positive (HR+), HER2-negative, Node-positive Breast Cancer in SWOG S1007 (RxPONDER). Kalinsky K, Barlow W, Puri R, Mitra A, Home T, Gralow J, Albain K, Hayes D, Delaloge S, Lin N, Perez E, Goldstein L, Chia S, Rastogi P, Schott A, Shak S, Tripathy D, Hortobagyi G, Meric-Bernstein F, Sharma P, Pusztai L, Thompson A, Pathak H, Godwin A. Submitted, 2025.



| | <i>\$1706</i> | S2007 | <i>S2206</i> | S2212 | A011801 | A012103 | A012301 | EA1211 | MA39 | NRGBR007 |
|---|---------------|-------|--------------|-------|---------|---------|---------|--------|------|----------|
| Arnot Ogden Medical Center/Falck Cancer Center | - | - | - | - | - | - | - | - | - | 1 |
| Banner MD Anderson Cancer Center | - | - | - | - | 12 | - | - | - | - | - |
| Banner University Medical Center - Tucson | 1 | - | - | - | - | - | - | - | - | - |
| Baptist Mem Health Care/Mid South Minority Underserved NCORP | 3 | - | 4 | 10 | - | - | - | 2 | - | - |
| Baylor College of Medicine/Duncan Comprehensive Cancer Center | - | - | 2 | 3 | 2 | 1 | - | - | 3 | - |
| Boston Medical Center | - | - | - | 1 | 6 | 1 | - | - | - | - |
| CWRU Case Comprehensive Cancer Center LAPS | - | 1 | - | - | - | - | - | - | 2 | - |
| Cancer Research Consortium of West Michigan NCORP | 1 | - | - | 13 | - | - | - | - | - | - |
| Cancer Research for the Ozarks NCORP | 3 | - | - | 6 | 1 | - | - | - | - | - |
| Cancer Research of Wisconsin and Northern Michigan Consortium | - | - | 1 | 7 | - | - | - | - | - | - |
| Carle Cancer Center NCI Community Oncology Research Program | - | 2 | 5 | 15 | - | - | - | - | - | - |
| Cedars-Sinai Medical Center | - | - | 7 | 4 | 1 | 1 | - | - | - | - |
| City of Hope Comprehensive Cancer Center | - | - | 2 | 13 | - | - | - | - | - | - |
| Columbia University Minority Underserved NCORP | 4 | - | 1 | 1 | - | - | - | - | - | - |
| CommonSpirit Health Research Institute | 2 | - | 1 | 9 | - | - | - | - | 2 | - |
| Dayton NCI Community Oncology Research Program | - | 1 | - | - | - | - | - | - | - | - |
| Desert Regional Medical Center | 1 | - | - | - | - | - | - | - | 1 | - |
| Essentia Health NCI Community Oncology Research Program | - | - | 1 | 2 | 1 | - | - | - | - | - |
| Fred Hutchinson Cancer Research Center LAPS | 5 | - | - | 4 | - | 6 | - | - | - | - |
| Georgia Cares Minority Underserved NCORP | - | - | - | 1 | - | - | - | - | - | - |
| Georgia NCI Community Oncology Research Program | 2 | - | 2 | 8 | - | 1 | - | - | - | - |
| Gulf South Minority Underserved NCORP | 1 | - | 3 | 8 | - | 1 | - | 1 | - | - |
| Hawaii Minority Underserved NCORP | - | - | - | 5 | - | - | - | 1 | - | 1 |
| Heartland Cancer Research NCORP | 4 | - | 7 | 23 | 1 | - | - | - | - | - |
| Henry Ford Health Providence Southfield Hospital | 2 | - | - | 2 | 2 | 2 | - | - | 3 | - |
| Henry Ford Hospital | - | - | 3 | 5 | - | 3 | - | - | - | - |
| Houston Methodist Hospital | - | - | - | - | 2 | 2 | - | - | 3 | 1 |
| Instituto Nacional De Cancerologia de Mexico | - | - | - | 5 | - | - | - | - | - | - |
| Kaiser Permanente NCI Community Oncology Research Program | - | - | - | 7 | - | - | - | - | - | - |
| Lahey Hospital and Medical Center | - | - | 1 | 2 | 1 | - | - | - | - | - |
| Loma Linda University Medical Center | - | - | - | 4 | - | - | - | - | - | - |
| Loyola University Medical Center | - | - | 1 | 1 | - | - | - | - | - | - |
| Medical University of South Carolina Minority Underserved NCORP | 1 | - | 2 | - | - | 1 | - | - | 7 | - |
| Michigan Cancer Research Consortium NCORP | 4 | - | 4 | 15 | - | - | - | - | - | - |
| Montana Cancer Consortium NCORP | 1 | - | - | 6 | - | - | 1 | - | - | - |



| | <i>\$1706</i> | S2007 | <i>S2206</i> | S2212 | A011801 | A012103 | A012301 | EA1211 | MA39 | NRGBR007 |
|---|---------------|-------|--------------|-------|---------|---------|---------|--------|------|----------|
| Mount Sinai Hospital | - | - | 2 | - | - | - | - | - | - | - |
| MultiCare Tacoma General Hospital | - | - | 4 | - | - | - | - | - | - | - |
| NCORP of the Carolinas (Prisma Health NCORP) | - | - | 5 | 8 | - | - | - | - | - | - |
| New Mexico Minority Underserved NCORP | 6 | 1 | - | - | - | 1 | - | - | - | - |
| Northwell Health NCORP | - | 1 | 3 | 5 | - | - | - | - | - | 2 |
| Northwestern University LAPS | 1 | 2 | - | 26 | 1 | 1 | - | - | - | - |
| Ohio State University Comprehensive Cancer Center LAPS | 3 | - | - | 7 | - | - | - | - | - | - |
| Oregon Health and Science University | - | - | 4 | 2 | - | - | - | - | - | 1 |
| Pacific Cancer Research Consortium NCORP | 2 | - | 9 | 19 | - | - | - | - | 4 | - |
| Regents of the University of Michigan | 3 | - | 3 | 2 | 2 | 3 | - | - | 14 | - |
| Rhode Island Hospital | - | - | - | 2 | - | - | - | - | - | - |
| Saint Joseph Hospital - Cancer Centers of Colorado | - | - | - | 9 | - | - | 1 | - | - | - |
| Southeast Clinical Oncology Research Consortium NCORP | - | 1 | 6 | 36 | 1 | - | - | - | - | - |
| Sutter Cancer Research Consortium | - | - | 1 | 3 | 3 | - | - | - | - | 3 |
| The Don and Sybil Harrington Cancer Center | 3 | - | - | - | 3 | - | - | - | - | - |
| The West Clinic - Wolf River | - | - | - | 20 | - | - | - | - | - | - |
| UC Davis Comprehensive Cancer Center LAPS | 7 | - | - | - | - | 3 | 4 | - | - | 1 |
| UC Irvine Health/Chao Family Comprehensive Cancer Center | - | 1 | 2 | - | 2 | - | - | - | - | - |
| UC San Diego Moores Cancer Center | - | - | - | - | - | - | - | - | 2 | - |
| UPMC Hillman Cancer Center LAPS | 1 | - | 3 | 4 | - | - | - | - | - | - |
| USC Norris Comprehensive Cancer Center LAPS | - | - | - | - | 1 | - | - | - | 4 | - |
| U of Alabama at Birmingham / Deep South Research Consort LAPS | - | 2 | - | 6 | - | - | - | - | - | - |
| University of Arkansas for Medical Sciences | 2 | - | - | 4 | 2 | 4 | - | - | - | - |
| University of Colorado Cancer Center LAPS | 1 | - | 1 | 3 | 1 | - | - | - | 2 | 3 |
| University of Kansas Cancer Center - MCA Rural MU NCORP | 4 | - | 8 | 11 | 1 | 2 | - | - | 5 | 3 |
| University of Oklahoma Health Sciences Center LAPS | 1 | - | 2 | 2 | - | - | - | 1 | - | - |
| University of Rochester LAPS | 1 | - | - | - | - | - | - | - | - | - |
| University of Texas Health Science Center at San Antonio | - | 4 | 6 | - | - | - | - | - | - | 7 |
| University of Texas MD Anderson Cancer Center LAPS | 1 | 2 | - | - | - | - | - | - | - | - |
| University of Utah - Huntsman Cancer Institute LAPS | 5 | - | - | - | 2 | - | - | - | - | - |
| Vanderbilt University - Ingram Cancer Center LAPS | - | - | - | - | 2 | - | - | - | - | - |
| Wayne State University - Karmanos Cancer Institute LAPS | - | - | 2 | 10 | 2 | - | - | 4 | 3 | - |
| Western States Cancer Research NCORP | - | - | - | - | - | - | - | - | 1 | - |
| Wisconsin NCI Community Oncology Research Program | 1 | - | - | 4 | - | - | - | - | - | - |
| Yale University - Yale Cancer Center LAPS | - | - | 4 | 24 | 3 | - | - | - | - | - |
| ALLIANCE | 18 | 7 | 28 | 141 | - | - | - | - | - | - |
| CCTG | 6 | - | - | - | - | - | - | - | - | - |
| ECOG-ACRIN | 11 | 3 | 34 | 111 | - | - | - | - | - | - |
| NRG | 48 | - | 19 | 82 | - | - | - | - | - | - |
| Total | 160 | 28 | 193 | 721 | 55 | 33 | 6 | 9 | 56 | 23 |



| | NRGBR008 | NRGBR009 |
|---|----------|----------|
| Arnot Ogden Medical Center/Falck Cancer Center | - | - |
| Banner MD Anderson Cancer Center | - | - |
| Banner University Medical Center - Tucson | - | - |
| Baptist Mem Health Care/Mid South Minority Underserved NCORP | 1 | - |
| Baylor College of Medicine/Duncan Comprehensive Cancer Center | - | - |
| Boston Medical Center | - | - |
| CWRU Case Comprehensive Cancer Center LAPS | - | - |
| Cancer Research Consortium of West Michigan NCORP | - | - |
| Cancer Research for the Ozarks NCORP | - | - |
| Cancer Research of Wisconsin and Northern Michigan Consortium | - | - |
| Carle Cancer Center NCI Community Oncology Research Program | - | - |
| Cedars-Sinai Medical Center | - | - |
| City of Hope Comprehensive Cancer Center | - | - |
| Columbia University Minority Underserved NCORP | - | - |
| CommonSpirit Health Research Institute | - | - |
| Dayton NCI Community Oncology Research Program | - | - |
| Desert Regional Medical Center | - | - |
| Essentia Health NCI Community Oncology Research Program | - | - |
| Fred Hutchinson Cancer Research Center LAPS | - | 3 |
| Georgia Cares Minority Underserved NCORP | - | - |
| Georgia NCI Community Oncology Research Program | - | - |
| Gulf South Minority Underserved NCORP | - | - |
| Hawaii Minority Underserved NCORP | - | - |
| Heartland Cancer Research NCORP | - | 1 |
| Henry Ford Health Providence Southfield Hospital | - | 2 |
| Henry Ford Hospital | - | - |
| Houston Methodist Hospital | - | - |
| Instituto Nacional De Cancerologia de Mexico | - | - |
| Kaiser Permanente NCI Community Oncology Research Program | - | - |
| Lahey Hospital and Medical Center | - | - |
| Loma Linda University Medical Center | - | 1 |
| Loyola University Medical Center | - | 1 |
| Medical University of South Carolina Minority Underserved NCORP | - | - |
| Michigan Cancer Research Consortium NCORP | - | - |
| Montana Cancer Consortium NCORP | - | - |
| Mount Sinai Hospital | - | - |
| MultiCare Tacoma General Hospital | - | - |
| NCORP of the Carolinas (Prisma Health NCORP) | - | - |
| New Mexico Minority Underserved NCORP | - | - |
| | | |

| | NRGBR008 | NRGBR009 |
|--|----------|----------|
| Northwell Health NCORP | - | - |
| Northwestern University LAPS | - | - |
| Ohio State University Comprehensive Cancer Center LAPS | - | - |
| Oregon Health and Science University | - | - |
| Pacific Cancer Research Consortium NCORP | - | - |
| Regents of the University of Michigan | - | - |
| Rhode Island Hospital | - | - |
| Saint Joseph Hospital - Cancer Centers of Colorado | - | - |
| Southeast Clinical Oncology Research Consortium NCORP | - | - |
| Sutter Cancer Research Consortium | - | 1 |
| The Don and Sybil Harrington Cancer Center | - | 3 |
| The West Clinic - Wolf River | - | 2 |
| UC Davis Comprehensive Cancer Center LAPS | - | - |
| UC Irvine Health/Chao Family Comprehensive Cancer Center | - | - |
| UC San Diego Moores Cancer Center | - | - |
| UPMC Hillman Cancer Center LAPS | - | - |
| USC Norris Comprehensive Cancer Center LAPS | - | - |
| U of Alabama at Birmingham / Deep South Research Consortium LAPS | - | - |
| University of Arkansas for Medical Sciences | - | - |
| University of Colorado Cancer Center LAPS | - | - |
| University of Kansas Cancer Center - MCA Rural MU NCORP | - | - |
| University of Oklahoma Health Sciences Center LAPS | - | - |
| University of Rochester LAPS | - | - |
| University of Texas Health Science Center at San Antonio | - | - |
| University of Texas MD Anderson Cancer Center LAPS | - | - |
| University of Utah - Huntsman Cancer Institute LAPS | - | - |
| Vanderbilt University - Ingram Cancer Center LAPS | - | - |
| Wayne State University - Karmanos Cancer Institute LAPS | - | 1 |
| Western States Cancer Research NCORP | - | - |
| Wisconsin NCI Community Oncology Research Program | - | - |
| Yale University - Yale Cancer Center LAPS | - | - |
| ALLIANCE | - | - |
| CCTG | - | - |
| ECOG-ACRIN | - | - |
| NRG | - | - |
| Total | 1 | 15 |
| | | |

